Patents by Inventor Jim Kou

Jim Kou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Controlled release formulations of levodopa and uses thereof
    Patent number: 9901640
    Abstract: A modified release levodopa dosage form.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: February 27, 2018
    Assignee: Impax Laboratories, Inc.
    Inventors: Ann Hsu, Jim Kou, Laman Alani
  • CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF
    Publication number: 20170100480
    Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 13, 2017
    Inventors: Ann Hsu, Jim Kou, Laman Alani
  • Controlled release formulations of levodopa and uses thereof
    Patent number: 9533046
    Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: January 3, 2017
    Assignee: Impax Laboratories, Inc.
    Inventors: Ann Hsu, Jim Kou, Laman Alani
  • CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF
    Publication number: 20160089438
    Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
    Type: Application
    Filed: December 4, 2015
    Publication date: March 31, 2016
    Inventors: Ann Hsu, Jim Kou, Laman Alani
  • Pharmaceutical Formulations and Compositions of a Selective Antagonist of Either CXCR2 or Both CXCR1 and CXCR2 and Methods of Using the Same for Treating Inflammatory Disorders
    Publication number: 20080021100
    Abstract: The present invention provides compositions as well as kits and methods based on a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 that are useful for treating inflammatory disorders.
    Type: Application
    Filed: June 12, 2007
    Publication date: January 24, 2008
    Inventors: Jim Kou, Jonathan Eichman
  • Stable extended release oral dosage composition
    Publication number: 20060159761
    Abstract: A film-coated extended release solid oral dosage composition containing a nasal decongestant, pseudoephedrine or salt thereof, e.g., pseudoephedrine sulfate in a core effective to provide a geometric maximum plasma concentration of pseudoephedrine of about 345 ng/mL to about 365 ng/mL at a time of about 7.60 hrs to about 8.40 hrs and having two or three film-coatings on the core, the second one containing an amount of the non-sedating antihistamine, desloratadine, effective to provide a geometric maximum plasma concentration of desloratadine of about 2.15 ng/mL to about 2.45 ng/mL at a time of about 4.0 hours to about 4.5 hours, and use of the composition for treating patients showing the signs and symptoms associated with allergic and/or inflammatory conditions of the skin and airway passages are disclosed.
    Type: Application
    Filed: October 6, 2005
    Publication date: July 20, 2006
    Inventor: Jim Kou
  • Pharmaceutical compositions
    Publication number: 20060009504
    Abstract: Disclosed are useful pharmaceutical compositions.
    Type: Application
    Filed: December 17, 2004
    Publication date: January 12, 2006
    Inventors: Susan Heimbecher, Jim Kou, Irina Kazakevich